Aakash Babu has covered the pharmaceutical sector since 2018, starting his career at Reuters, where he specialised in tackling company news. Just before joining the Citeline team, he worked as a healthcare analyst at the Economist Group, focusing on disease trends, drug development, regulatory changes and pharmaceutical pricing. He has a master’s in economics and a post-graduate specialisation in business journalism from Asian College of Journalism-Bloomberg. He was a key member of the team that covered the initial breakthroughs in COVID-19 vaccine research during his time at Reuters. He also has experience in forecasting regulatory trends, drug approvals and pharmaceutical sales. Outside of work he enjoys traveling, writing and watching football.
Latest from Aakash Babu
After mandating mail back envelopes be available, the FDA now is considering whether disposal options that would allow opioids to be thrown in the trash also should be required, potentially adding to the expense for sponsors.
Newer launches in its pharmaceuticals division such as Nubeqa and Kerendia will be core to Bayer’s 2026 growth strategy.
While investment promises appear to be in billions of dollars, industry experts remain skeptical.
While investment promises appear to be in billions of dollars, industry experts remain skeptical.
The Trump administration has launched TrumpRx, a website the White House says could help save Americans billions in pharmaceutical spending, although it does not itself sell or dispense drugs.
The Trump administration has launched TrumpRx, a website the White House says could help save Americans billions in pharmaceutical spending, although it does not itself sell or dispense drugs.